Related Experiment Video
Updated: Jul 2, 2025
05:19
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
10.3K
HES4 is a potential biomarker for bladder cancer: a Mendelian randomization study
Zhiyong Tan1,2,3, Xiaorong Chen4, Haihao Li1,2,3
1Department of Urology, The Second Affiliated Hospital of Kunming Medical University, No. 347, Dianmian Street, Wuhua District, Kunming, 650101, Yunnan, People's Republic of China.
Journal of Cancer
|February 19, 2024
Summary
This study identified HES4 as a novel biomarker for bladder cancer (BLCA) diagnosis and prognosis. HES4 expression impacts the immune microenvironment and offers a new target for BLCA treatment.
Area of Science:
- Oncology
- Genetics
- Bioinformatics
Background:
- Bladder cancer (BLCA) presents a poor prognosis with limited therapeutic advancements.
- Identifying reliable diagnostic and prognostic biomarkers is crucial for improving patient outcomes.
Purpose of the Study:
- To identify a novel biomarker for bladder cancer (BLCA) diagnosis and prognosis.
- To investigate the causal relationship between gene expression and BLCA using Mendelian randomization (MR).
Main Methods:
- Utilized Mendelian randomization (MR) and transcriptome analysis on TCGA-BLCA and GSE121711 datasets.
- Performed genome-wide association study (GWAS) data analysis for BLCA outcome.
- Employed Cox regression and constructed a nomogram for prognostic factor assessment.
Main Results:
- HES4 was identified as a significant biomarker and independent prognostic factor for BLCA.
- HES4 expression correlated with immune cell populations and pathways, including immune response and cancer pathways.
- HES4 was found to be upregulated in BLCA samples.
Conclusions:
- HES4 serves as a valuable independent prognostic factor for bladder cancer (BLCA).
- This discovery provides critical insights for future research and therapeutic strategies in BLCA treatment.
